drugset / Trial / NCT00542269
Efficacy and Safety of Aliskiren/Ramipril/Amlodipine Compared With Ramipril/Amlodipine and Aliskiren/Amlodipine in Patients With Metabolic Syndrome
RandomizedParallel-groupTriple-blindTreatment
Summary
This proof of concept study is designed to evaluate the efficacy and safety of the combination therapy of aliskiren and ramipril as add-on to amlodipine in the treatment of patients with essential hypertension and metabolic syndrome who do not respond adequately to amlodipine monotherapy.
Timeline
- Start
- 2008-03
- Primary completion
- 2009-07
- Completion
- 2009-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aliskiren | Small molecule | 300 mg | Oral |
| Subject | Ramipril | Small molecule | 10 mg | Oral |
| Background | Amlodipine | Other / unclassified | 5 mg | Oral |
| Background | Amlodipine | Other / unclassified | 10 mg | Oral |